Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected Persons in Routine Clinical Care

Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected Persons in Routine Clinical Care

Background: Effectiveness of antiretroviral therapy (ART) in a routine clinical care may result different from the clinical trials. We assessed the virologic outcomes in treatment-naive persons who received either efavirenz (EFV) or atazanavir/ritonavir (ATV/r) with a backbone of tenofovir/emtricita...

Full description

Bibliographic Details
Main Authors:	Toshibumi Taniguchi MD, Jessica R. Grubb MD, Diana Nurutdinova MD, Nur F. Önen MD, Enbal Shacham PhD, Michael Donovan BS, Edgar Turner Overton MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2013-03-01
Series:	Journal of the International Association of Providers of AIDS Care
Online Access:	https://doi.org/10.1177/1545109712467057

Similar Items

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
by: Tasker Sybil, et al.
Published: (2009-06-01)

The Relationship of Social Support and Neighborhood Perceptions among Individuals with HIV
by: Enbal Shacham PhD, et al.
Published: (2017-09-01)

Psychiatric Diagnoses among an HIV-Infected Outpatient Clinic Population
by: Enbal Shacham PhD, et al.
Published: (2016-03-01)

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
by: Muche Belete A, et al.
Published: (2021-02-01)

Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS
by: Saif Ahmad Khan, et al.
Published: (2020-11-01)

Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
by: Dimitrios Pilalas, et al.
Published: (2018-01-01)

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
by: Takeshi Nishijima, et al.
Published: (2013-01-01)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)

Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
by: Yohei Hamada, et al.
Published: (2013-01-01)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
by: Miriam Samuel, et al.
Published: (2014-01-01)

Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers
by: Ingrid F. Metzger, PhD, et al.
Published: (2014-12-01)

Boosting with Naive Regression
by: Jian-Hong Lin, et al.
Published: (2007)

Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study.
by: Laurent Hocqueloux, et al.
Published: (2012-01-01)

Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection
by: G F Moshkovich, et al.
Published: (2014-11-01)

Total Hip Arthroplasty Outperforms Hemiarthroplasty in Patients Aged 65 Years and Older: A Propensity-Matched Study of Short-Term Outcomes
by: Jared A. Warren DO, et al.
Published: (2019-09-01)

Abakavir och lamivudin i kombination med efavirenz eller atazanavir vid behandling av HIV. : En jämförande litteraturstudie om effekt och säkerhet
by: Simu, Elin
Published: (2016)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
by: Rebecca Zash, MD, et al.
Published: (2018-07-01)

Robustification of Naïve Bayes Classifier and Its Application for Microarray Gene Expression Data Analysis
by: Md. Shakil Ahmed, et al.
Published: (2017-01-01)

Can a technical analysis-based trading strategy outperform a naive buy-hold strategy
by: Gross, Peter
Published: (2011)

Backstabbed: routine lumbar puncture complicated by retroperitoneal hematoma and hemorrhagic shock
by: George Horani, MD, et al.
Published: (2021-08-01)

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
by: Alicia Gutierrez-Valencia, et al.
Published: (2018-01-01)

Severe Skin Rash Associated with Atazanavir
by: Andrew Walkty, et al.
Published: (2009-01-01)

Role of atazanavir in the treatment of HIV infection
by: Pablo Rivas, et al.
Published: (2008-12-01)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)<sub>2 </sub>vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
by: Focà Emanuele, et al.
Published: (2012-02-01)

Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
by: Cristina Gervasoni, et al.
Published: (2015-01-01)

Routine Type and Screens Are Unnecessary for Primary Total Hip and Knee Arthroplasties at an Academic Hospital
by: Zachary K. Christopher, MD, et al.
Published: (2020-12-01)

Giant annular lichenoid drug eruption caused by efavirenz therapy
by: Emily Baumrin, MD, et al.
Published: (2018-04-01)

Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?
by: Ugo Giovanni Falagario, et al.
Published: (2021-01-01)

Deep Learning for Classification of Bone Lesions on Routine MRI
by: Feyisope R. Eweje, SB, et al.
Published: (2021-06-01)

Utility of Routine Pathologic Specimens in Ganglion Wrist Excisions
by: Darren B. LePere, MD, et al.
Published: (2020-09-01)

Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
by: Ling Xu, et al.
Published: (2021-01-01)

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
by: Frank van Leth, et al.
Published: (2004-10-01)

Efavirenz in pregnancy
by: Polly Clayden, et al.
Published: (2010-11-01)

An inverted appendix found on routine colonoscopy: A case report with discussion of imaging findings
by: Clement Tran, MD, et al.
Published: (2019-08-01)

Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
by: Anita J Brogan, et al.
Published: (2018-01-01)

The Feasibility and Safety of Routine Thoracic Surgeries in the Low-Risk Areas During the Coronavirus Disease 2019 Pandemic
by: Yiyang Wang, MD, et al.
Published: (2021-03-01)

PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS
by: N. E. Uvarova, et al.
Published: (2018-12-01)

The strategy of pharmaceutical patent protection: the case of atazanavir
by: Carla Cristina de Freitas da Silveira, et al.
Published: (2016-03-01)

Routine Laser-assisted Indocyanine Green Angiography in Immediate Breast Reconstruction: Is It Worth the Cost?
by: Shayda Mirhaidari, MD, et al.
Published: (2019-04-01)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
by: Joshua A Beckman, et al.
Published: (2017-01-01)